Financial health
- Operating income covered interest expense -157.3× in the latest year, down from -13.0× 3 years ago.
MREO Financials Mereo BioPharma Group plc
4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $500000 | $42M | 0.0% | -8021.4% | 102.4% | 91.2% | -$31M | — | $41M |
| 2024 | $0 | $43M | — | — | 70.9% | 56.6% | -$33M | — | $70M |
| 2023 | $10M | $29M | 0.0% | -284.2% | 58.3% | 44.3% | -$21M | — | $57M |
| 2022 | $0 | -$42M | — | — | -82.1% | -54.5% | -$49M | — | $68M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $0 | -$7M | — | — | -24.4% | -20.2% | -$6M | — | $30M |
| Mar '26 | — | -$7M | — | — | -19.7% | -16.5% | -$4M | — | $30M |
| Dec '25 | $0 | -$7M | — | — | -18.0% | -16.0% | -$8M | — | $41M |
| Sep '25 | $0 | -$7M | — | — | -15.1% | -13.1% | -$7M | — | $49M |
| Jun '25 | $500000 | -$15M | 0.0% | -2099.8% | -27.0% | -23.3% | -$8M | — | $56M |
| Mar '25 | — | -$13M | — | — | -21.4% | -18.9% | -$8M | — | $62M |
| Dec '24 | $0 | -$7M | — | — | -11.6% | -9.2% | -$9M | — | $70M |
| Sep '24 | $0 | -$15M | — | — | 20.7% | -16.9% | -$8M | — | $81M |
| Jun '24 | $0 | -$12M | — | — | -15.6% | -12.7% | -$8M | — | $87M |
| Mar '24 | $0 | -$9M | — | — | -20.9% | -16.0% | -$8M | — | $49M |
| Dec '23 | $1M | -$9M | 0.0% | -712.8% | -18.0% | -13.7% | — | — | $57M |
| Sep '23 | $0 | -$7M | — | — | -11.9% | — | — | — | — |
| Jun '23 | $9M | -$2M | 0.0% | -9.0% | -3.5% | — | — | — | — |
| Mar '23 | $0 | -$12M | — | — | -27.2% | — | — | — | — |
Valuation over time
How the market has priced MREO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 103.1× (Jan '24) to 5.5× (Nov '26).
- The price-to-sales ratio has risen from 303.8× (Jan '24) to 463.7× (Nov '26).
P/E
P/S
Frequently asked questions
Is MREO growing its revenue and profit?
See the revenue and net-income charts above for Mereo BioPharma Group plc's multi-year trend.
How much debt does MREO have?
As of FY2025, Mereo BioPharma Group plc reported — of total debt against $41M of cash; operating income covered interest expense -157.3×.
What is MREO's profit margin?
In FY2025, gross margin was —, operating margin -8021.4%, and net margin 8375.6%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.